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Abstract
In the high malaria-transmission settings of sub-Saharan Africa, malaria in pregnancy is an important
cause of maternal, perinatal and neonatal morbidity. Intermittent preventive treatment of malaria
in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) reduces the incidence of low birth-
weight, pre-term delivery, intrauterine growth-retardation and maternal anaemia. However, the
public health benefits of IPTp are declining due to SP resistance. The combination of azithromycin
and chloroquine is a potential alternative to SP for IPTp. This review summarizes key in vitro and in
vivo evidence of azithromycin and chloroquine activity against Plasmodium falciparum and Plasmodium
vivax, as well as the anticipated secondary benefits that may result from their combined use in IPTp,
including the cure and prevention of many sexually transmitted diseases. Drug costs and the
necessity for external financing are discussed along with a range of issues related to drug resistance
and surveillance. Several scientific and programmatic questions of interest to policymakers and
programme managers are also presented that would need to be addressed before azithromycin-
chloroquine could be adopted for use in IPTp.
Background
Each year, 30 million pregnancies are at risk of malaria
infection in sub-Saharan Africa, representing a major pub-
lic health problem. Malaria in pregnancy (MIP) is associ-
ated with low birth-weight (LBW) [1-3], pre-term delivery
[4] intrauterine growth-retardation [4,5], and maternal
anaemia [6]. LBW is a strong predictor of infant mortality
in sub-Saharan Africa; death within the first year of life is
three-times higher for LBW newborns compared to
neonates of normal birth-weight [7]. Malaria is one of the
few contributors to LBW that can be improved by specific
interventions [8]. Thus, to reduce the effects of MIP in
endemic areas, the World Health Organization (WHO)
recommends use of Intermittent Preventive Treatment of
Malaria in Pregnancy (IPTp) with sulphadoxine-
pyrimethamine (SP).
IPTp has two primary objectives: (1) to clear asympto-
matic peripheral and placental parasitaemia and (2) to
provide intermittent chemoprophylaxis against malaria
infection during pregnancy. The WHO recommends
administration of two or three courses of SP, sulphadox-
ine (500 mg) and pyrimethamine (25 mg), after foetal
quickening with each course given no less than one
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month apart, and all prior to the last month of pregnancy
[9]. Anti-malarial chemoprophylaxis among paucigravi-
dae increases birth-weight by an average of 127 g (95% CI
88.64 to 164.75 g) and reduces, by nearly half, the inci-
dence of LBW (RR = 0.57, 95% CI 0.46 to 0.72) [10]. It has
been estimated that universal coverage with IPTp would
reduce all-cause neonatal mortality by 32% (95% CI -1 to
54%) [11].
Standard IPTp dosing does not provide the same degree of
protective efficacy for pregnant women who are HIV-pos-
itive. This can be overcome, however, by administering
more frequent courses of SP throughout pregnancy. A
study in Malawi compared monthly SP treatment versus
two courses during the antenatal period among HIV-pos-
itive and HIV-negative women. An estimated 7.8% of
HIV-positive pregnant women had placental malaria after
receiving monthly SP as compared to 21.5% of HIV-posi-
tive women who received two doses of SP (RR, 0.36 [95%
CI, 0.17–0.79]). Among HIV-negative women, 2.3% who
received monthly SP had placental parasitaemia in con-
trast to 6.3% of HIV-negative women who received two-
dose SP (RR, 0.37 [95% CI, 0.11–1.19]) [8].
The benefits of IPTp are threatened by increasing resist-
ance of Plasmodium falciparum to SP. In many countries,
artemisinin combination therapy (ACT) has replaced SP
for case management, according to WHO guidelines,
because SP now demonstrates inadequate therapeutic effi-
cacy in children [12]. Therapeutic efficacy of SP in chil-
dren with clinical cases of P. falciparum malaria does not,
however, predict efficacy of IPTp. Correlation analysis
between paediatric treatment and IPTp suggests that SP
may still offer some protection against MIP in geographic
areas where day 14 post-treatment failure rates for SP in
children are as high as 40% [13]. This protection, how-
ever, is not uniform across populations; primigravidae are
particularly vulnerable to the effects of MIP and are pro-
tected the least by SP where sensitivity is on the decline. In
Ghana, where parasite sensitivity to SP remains higher
than in east and southern Africa, uncorrected parasitolog-
ical failure rates by day 28 post-treatment were 36.4% (32
of 88) in children, 27.1% (29 of 107) in primigravidae,
6.1% (3 of 49) in secundigravidae, and 3.8% (2 of 52) in
multigravidae [14]. Thus, SP is already compromised and
an urgent need exists to identify alternative compounds
for use in IPTp, even though SP still offers some protec-
tion up to an unknown threshold of parasite resistance.
An ideal anti-malarial drug or drug combination for IPTp
should be safe, well tolerated, efficacious in the clearance
of malaria parasites, provide a long period of chemopro-
tection and, preferably, not be deployed as the first-line
treatment for clinical malaria. If a drug or drug combina-
tion used in IPTp is not simultaneously used for clinical
malaria case management, then IPTp may actually lower
the selection pressure on the first-line drug by decreasing
symptomatic cases that require treatment. This is particu-
larly important as countries increasingly treat pregnant
women with uncomplicated clinical malaria in second-
and third-trimesters with ACTs.
Several published reviews of drugs for IPTp have included
azithromycin and chloroquine, although only as mono-
therapies [15-18]. This review summarizes in vitro and in
vivo evidence for the therapeutic efficacy of azithromycin
and chloroquine when used alone or together and dis-
cusses the additional benefits that the combination could
have on many sexually transmitted diseases and, possibly,
pneumococcal infection during pregnancy. Drug costs are
presented along with issues related to drug resistance and
surveillance. Several scientific and programmatic areas are
outlined, as well, that would need to be addressed for pol-
icymakers and programme managers before azithromy-
cin-chloroquine could be adopted for use in IPTp.
Azithromycin monotherapy for treatment and prevention 
of malaria
Pharmacokinetics
Azithromycin is a slow-acting anti-malarial macrolide
[19], an analogue of erythromycin with a nitrogen atom
inserted into the macrolide nucleus. As a result, there is
enhanced penetration of drug into macrophages, fibrob-
lasts and polymorphonuclear neutrophils, permitting
greater accumulation within acidified vacuoles and
extending the 1.5-hour half-life of erythromycin to 68
hours for azithromycin [20]. Stable at gastric pH, azithro-
mycin has an absolute bioavailability of 37% following
oral administration [21]. It accumulates in hepatic, renal,
pulmonary and splenic tissue [22], and gradually leaches
into the bloodstream over a period of one week [23]. Mild
renal dysfunction and mild-to-moderate hepatic dysfunc-
tion do not affect excretion significantly.
Among pregnant women, serum concentrations peak
within six hours of oral administration and are sustained
for 24 hours. As the drug disperses, peak concentrations
are maintained three-times longer in the placenta, myo-
metrial and adipose tissues [24]; only 2.6% of a maternal
dose, however, perfuses the placenta [25]. Azithromycin is
excreted in human milk with no adverse events observed
as a consequence [26].
Azithromycin targets the 70 S ribosomal subunit of the
apical complex of susceptible micro-organisms including
P. falciparum and P. vivax [23]. Once attached to the api-
coplasts of the parasite, azithromycin hinders polypeptide
development, triggering premature detachment and
movement down the peptide exit tunnel. The potency of
azithromycin, as a translation inhibitor, is greatest against
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the progeny of parasites that inherit a non-functioning
apicoplast following drug exposure, thus creating a
delayed-death effect [27-29]. Laboratory-generated P. fal-
ciparum that are resistant to azithromycin appear to accu-
mulate mutations after in vitro passage in the structural
proteins of the ribosome [23]. It is unknown whether
mutations induced by azithromycin are capable of under-
mining the inhibitory action of other drugs that also target
the apicoplast.
Safety and tolerability
Doses of azithromycin between 500 mg and 2,000 mg
have been used in all trimesters of human pregnancy for
the treatment of upper and lower respiratory tract infec-
tions, skin diseases, Chlamydia trachomatis, mycoplasma
and group B streptococci infections among women aller-
gic to other antibiotics.
Meta-analysis of eight randomized clinical trials among
pregnant women with C. trachomatis infection found that
azithromycin was associated with fewer gastrointestinal
adverse events than erythromycin (OR = 0.11, 95% CI
0.07–0.18) and fewer total adverse events (OR = 0.11,
95% CI 0.07–0.18) [30]. A placebo-controlled trial, how-
ever, suggests that azithromycin may be poorly tolerated
by HIV-positive patients. Gastrointestinal effects were
reported by 78.9% of azithromycin recipients (67 of 85)
and 27.5% of participants given placebo (24 of 89) [31].
Although an unusual side-effect, case reports indicate that
HIV-positive patients may experience temporary ototoxic-
ity with azithromycin use [32].
Adults treated with a 1,000 mg oral dose of azithromycin
report moderate side-effects including diarrhoea or loose
stools (7%), nausea (5%), vomiting (2%), and vaginitis
(2%); up to 1% of adults experience dizziness, headache,
vertigo, and somnolence [33]. There is no evidence of ter-
atogenicity in animal models, even at four-times the
human treatment dose [34-36].
Efficacy
The in vitro anti-malarial activity of azithromycin
increases 200-fold against P. falciparum isolates when
incubated between 24 and 48 hours, while its 50% inhib-
itory concentration values drop as low as 35 nanomolar
[37]. At 48-hours, azithromycin is 10-fold more active
than erythromycin against chloroquine-resistant P. falci-
parum; the two compounds are equipotent, however,
when chloroquine-sensitive parasites are exposed to the
same drug concentration [38,39].
Daily regimens of 250 mg with a loading dose of 500 or
750 mg have shown an impressive chemoprophylactic
effect against P. vivax. Azithromycin had a 99% protective
effect (95% CI, 93% to 100%) among semi-immune sub-
jects in Indonesia over a 20-week period [40]. A similar
protective efficacy, 98% (95% CI, 88% to 100%), was
seen in Thailand [41] in a semi-immune population. By
comparison, the chemoprophylactic effect of azithromy-
cin against P. falciparum has shown promise, but has been
less impressive (Table 1).
The first published P. falciparum human challenge study
with azithromycin involved four non-immune volunteers
who received a loading dose of 500 mg and 250 mg daily
for three days. Subjects were then inoculated with five
Anopheles stephensi mosquitoes that had an average of 3.2
salivary-gland P. falciparum sporozoites each, after which
they continued to receive 250 mg of azithromycin daily
for four more days. With unquantifiable plasma concen-
trations of azithromycin, presumably due to poor absorp-
tion, one of four subjects developed parasitaemia in the
14-day post-challenge period [42].
A subsequent trial suggested that a regimen of longer
duration might be required against P. falciparum. Ten non-
immune subjects were given a loading dose of 500 mg fol-
lowed by 250 mg daily for 2 weeks prior to parasite expo-
sure. After inoculation, 250 mg was administered daily for
one additional week, producing a protective effect of 40%
(95% CI, 12% to 74%). A concurrent human challenge
study with 10 non-immune subjects was conducted using
the same regimen, except that 250 mg was given daily for
two weeks post-exposure, rather than for just one, produc-
ing a 100% protective effect [43]. This high level of protec-
Table 1: Chemoprophylactic effect of azithromycin monotherapy against Plasmodium falciparum in semi-immune non-pregnant adults.
Country Treatment regimen Sample size Duration of follow-up Chemoprophylactic effect (95% CI)
Kenya [40] 250 mg daily 59 10 weeks 83% (68–91)
Kenya [40] 1,000 mg weekly 58 10 weeks 64% (47–77)
Indonesia [36] 750 mg loading dose and 250 mg daily 148 20 weeks 72% (50–84)
Thailand [37] 750 mg loading dose and 250 mg daily 179 20 weeks 71% (-14–94)
Malaria Journal 2008, 7:255 http://www.malariajournal.com/content/7/1/255
Page 4 of 14
(page number not for citation purposes)
tion has not been replicated in the field, however, where
multiple infections may be expected.
Among semi-immune populations, an equivalent or
higher loading dose with the same daily regimen resulted
in protective efficacies of 83% (95% CI, 69% to 91%) in
Kenya [44], 71% (95% CI, -14% to 94%) in Thailand
[41], and 72% (95% CI, 50% to 84%) in Indonesia [40].
There were two sub-populations in the Indonesian study
which may have had slightly different degrees of acquired
immunity: the chemoprophylactic effect among soldiers
living for six months in the study area was 62.9% (95%
CI, 29.5 to 80.4) while chemoprophylactic protection
among civilians residing in the study area for less-than 18
months was 88.4 (95% CI, 56.6 to 97.4). The Kenyan trial
also evaluated weekly dosing with 1,000 mg of azithromy-
cin, in contrast to a daily regimen of 250 mg, producing
just 64% protective efficacy (95% CI, 47% to 77%) [44].
Despite relatively poor in vivo protection against P. falci-
parum in field settings, the favourable safety profile of azi-
thromycin in pregnant women and young children
prompted further investigation into molecules that might
be co-administered with azithromycin to improve its pro-
tective effect.
Chloroquine as monotherapy for the treatment and 
prevention of malaria
Pharmacokinetics
Chloroquine has been the first-line treatment of malaria
in much of the world for most of the past 60 years. Abso-
lute bioavailability is 70 to 75% while peak plasma con-
centrations are reached within two hours of oral
administration. A single therapeutic dose against a chloro-
quine-resistant strain will persist six to 10 days in the
blood, while its overall half-life is between one and two
months [45,46]. Chloroquine accumulates extensively in
the liver, connective tissue and pigmented tissue such as
skin and retina, enabling enormous total volume distribu-
tion. Greatest concentrations are found in erythrocytes,
granulocytes and platelets, and 55% is protein-bound in
plasma.
Chloroquine is active against erythrocytic life stages of
Plasmodium species when haemoglobin is being actively
digested. Haem is a toxic bi-product of haemoglobin
ingestion and must be eliminated through dimerization.
Under normal circumstances, parasites bio-crystallize
haem to form haemozoin, the iron-containing pigment
that accumulates as non-toxic cytoplasmic granules. Chlo-
roquine prevents this process by concentrating at
nanomolar levels outside parasites (10-9) and one million
times higher (10-3) in parasite food vacuoles of infected
erythrocytes [47]. Inside parasite vacuoles, chloroquine
binds to haem, preventing its expulsion. Thus, the more
haemoglobin ingested by parasites, the more toxic their
food vacuoles become, rapidly causing cell death. Resist-
ance to chloroquine is associated with polymorphisms in
the P. falciparum food vacuole transporter protein (pfcrt)
located on chromosome 7 [48]. All pfcrt alleles from chlo-
roquine-resistant strains, regardless of geographic origin,
encode a conserved K76T amino acid substitution. The
effect of pfcrt on chloroquine pharmacokinetics remains
disputed. Some researchers have theorized that pfcrt ena-
bles protonated chloroquine to escape the food vacuole
while others argue pfcrt binds directly to chloroquine,
thereby inhibiting its ability to alter food vacuole pH [49].
Safety and tolerability
Chloroquine is safe and generally well tolerated in treat-
ment doses. Due to its rapid absorption, chloroquine has
a narrow therapeutic index, increasing the potential for
toxic overdose. Hypotension and cardiac failure can be
prompted by a single oral dose of 3500 mg [50]. Despite
toxicity at high doses, the most commonly reported side-
effect in African populations is pruritus which peaks 24
hours after intake [51]. Chloroquine has been used safely
in all trimesters of human pregnancy for decades as both
a treatment and chemoprophylactic drug, crossing the
placenta without teratogenic effect [52].
Prior to establishment of IPTp in sub-Saharan Africa, chlo-
roquine was commonly given to pregnant women during
antenatal visits in sachets containing four weekly doses of
300 mg for self-administration. Compliance with chloro-
quine remained low for many reasons including pruritus
and its bitter taste which some women associate with
medications that induce abortion [53,54].
Efficacy
Although still a first-line treatment for P. vivax, chloro-
quine is no longer recommended for treatment of P. falci-
parum due to high levels of resistance. In combination
with another anti-malarial drug, however, chloroquine
might, once again, have a role in malaria control. Malawi
changed its first-line drug to SP in 1993 when chloro-
quine in vivo failure rates were as high as 58% [55]. Five
years later, chloroquine inhibited in vitro blood schizont
development in 96.5% (28 of 29) of isolates from Malawi
[56], indicating that pfcrt was no longer under selection
pressure. In 2001, field sampling failed to find parasites
carrying the pfcrt mutation associated with resistance [57]
and a clinical trial using chloroquine monotherapy was
100% efficacious (63 of 63) among asymptomatic semi-
immune adults who received 600 mg on day 0 and day 1,
and 300 mg on day 2 [58]. Most recently, a study in 2005
showed chloroquine to clear parasite infection in 98.8%
(79 of 80) of Malawi children with uncomplicated P. fal-
ciparum malaria [59].
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The re-emergence of high in vitro sensitivity to chloro-
quine in Malawi – within just five years – suggests the pfcrt
resistance mutation involves considerable fitness cost to
P. falciparum [60-62]. This micro-evolutionary reversal is
all the more remarkable because it occurred despite the
continued availability of chloroquine in the formal and
informal private sector. It is likely that P. falciparum sensi-
tivity will return elsewhere in the region, if it has not
already, with the declining chloroquine use.
Chloroquine monotherapy continues to demonstrate
modest therapeutic utility in west Africa. A recent observa-
tional study in Benin examined the effect of self-adminis-
tered chloroquine chemoprophylaxis among pregnant
women (N = 1090), comparing self-reported dosing over
pregnancy with birth weights. An estimated 49.9% of
women reported taking weekly chloroquine in the first tri-
mester, increasing to 92% of women in the second trimes-
ter and 97.5% in the final trimester. Random testing of
urine samples at delivery established a point-prevalence
for chloroquine use. In total, an estimated 99% of women
had ingested chloroquine (N = 166); of these, 72% had
levels consistent with consuming 300 mg in the previous
seven days. Subjects with self-reported chemoprophylac-
tic use for seven or more months were four times more
likely to give birth to child of normal birth weight (> 2500
grams) than women who used chemoprophylaxis for less
than four months (adjusted OR = 3.96; 95% CI = 1.9 to
8.28; p =< 0.001) [63].
Parasitological evidence of chloroquine efficacy was
reported, as well, in a recent four-arm clinical trial con-
ducted in Ghana among pregnant women with asexual P
falciparum stage parasitaemia. Women randomized to a
chloroquine treatment group (N = 225) received 600 mg
for 2 days and 300 mg on the third day. The uncorrected
day-28 treatment failure rate was 30% (62 of 208).
Polymerase chain reaction (PCR) analysis confirmed that
14% (30 of 208) were treatment failures while 6% (11 of
208) were re-infections. PCR was unable to distinguish
cases of recrudescence from new infection in the remain-
ing 10% (21 of 208) [64].
Potential for azithromycin and chloroquine when used in 
combination for the prevention of malaria
Evidence for synergy of the combination in vitro
An additive effect between azithromycin and chloroquine
has been shown in sensitivity testing conducted over a 48-
hour period. When incubation is extended to 68 hours,
drug synergy has been seen against chloroquine-resistant
isolates; the combination remains additive, however,
against chloroquine-sensitive parasites [65]. Sidhu et al in
contrast, observed an additive effect at 96 hours of incu-
bation against chloroquine-resistant isolates [23].
Azithromycin and chloroquine do not exhibit any clini-
cally relevant pharmacokinetic interactions [66], although
chloroquine resistance is reversible with calcium channel
blockers, such as verapamil and desipramine, that inhibit
p-glycoprotein-mediated efflux [67,68]. Azithromycin is a
p-glycoprotein substrate [69] which may suggest the pres-
ence of a metabolic mechanism for synergy. Whether
additive or synergistic, complete parasitological clearance
using the combination would not be expected in less than
48 hours, the equivalent of two schizogenesis cycles. Thus,
a conservative approach to in vivo dosing may require a
three-day regimen to realize the full benefits of the azi-
thromycin-chloroquine combination against P. falciparum
while minimizing the opportunity for survival of wild-
type progeny.
Evidence for synergy of the combination in vivo
A two-stage trial in India demonstrated in vivo synergy
between azithromycin and chloroquine against P. falci-
parum infection. The first stage, which was double-
blinded, included 32 semi-immune subjects treated for
uncomplicated P. falciparum malaria with either azithro-
mycin (1,000 mg) plus chloroquine placebo on days 0, 1
and 2, or chloroquine (600 mg) on days 0, 1 and 300 mg
on day 2 plus azithromycin placebo on days 0, 1 and 2.
The second stage of the trial was open label and included
64 semi-immune subjects who received the azithromycin-
chloroquine combination therapy in doses equal to stage
one. Treatment response rates at day 28 showed in vivo
synergy: 33% of those who received azithromycin mono-
therapy remained free of fever by day 28 compared to
27% in the chloroquine-treatment group. In contrast,
97% of patients who received drugs co-administered had
resolved fever and parasitaemia by day 7 with no observed
recrudescence by day 28. Parasitological responses by
treatment group mirrored the synergy of clinical observa-
tions. Azithromycin monotherapy eradicated parasites in
19% of subjects (3 of 16) by day 3, increasing to 63% of
subjects (10 of 16) by day 7, and dropping to 36% at day
28. As would be expected, chloroquine monotherapy was
faster-acting than azithromycin alone, but it also demon-
strated an increase in failures by day 28. Specifically, 56%
of subjects (9 of 16) were free of parasites at day 3, fol-
lowed by 88% (14 of 16) at day 7 and, finally, 27% (4 of
15) by day 28. For subjects receiving azithromycin-chloro-
quine combination treatment, however, 97% parasitolog-
ical eradication was achieved by day 3 and sustained
through day 7 and day 28 [70].
Treatment trials with the azithromycin-chloroquine 
combination in Africa
A double-blinded multi-centre trial was held in Burkina
Faso, Ghana Mali, Kenya, Uganda, and Zambia to com-
pare the therapeutic efficacy and tolerability of azithromy-
cin-chloroquine with that of mefloquine [71]; a second,
Malaria Journal 2008, 7:255 http://www.malariajournal.com/content/7/1/255
Page 6 of 14
(page number not for citation purposes)
open-label, confirmatory trial was conducted in the same
countries, with the addition of Senegal [72]. Together,
these studies established an efficacious treatment course
for azithromycin-chloroquine against uncomplicated P.
falciparum infection: a fixed daily dose of 1,000 mg of azi-
thromycin and 600 mg of chloroquine taken for three
days. This treatment regimen represents a slightly higher
dose of chloroquine than has been commonly adminis-
tered. Most often, 25 mg of chloroquine is provided per kg
of body weight over a three-day period: 10 mg per kg on
days 1 and 2 with 5 mg per kg on day 3. The azithromycin-
chloroquine fixed dose contains a total of 1,800 mg of
chloroquine, an amount that would typically be given to
a person weighing 72 kg. The average weight of pregnant
women in the Ghana efficacy study [64] was 55.9 kilo-
grams. Thus, 600 mg per day over three days is 22.4%
more chloroquine than is in the typical treatment course.
Mefloquine was an appropriate comparator in these sub-
Saharan studies because it has not been used regularly in
the region and parasite sensitivity is likely quite high.
Mefloquine is also a potential candidate to replace SP in
IPTp. Preliminary results suggest that azithromycin-chlo-
roquine is non-inferior to mefloquine with P. falciparum
clearance rates comparable to those observed in India.
The azithromycin-chloroquine combination warrants fur-
ther investigation and may also offer particular advan-
tages in settings where mixed infections of P. falciparum
and P. vivax predominate.
The azithromycin-chloroquine combination for IPTp
Dosing
If azithromycin and chloroquine are used together in
IPTp, then an initial priority should be to identify the
most suitable dose of the combination. It seems likely that
a three-day treatment regimen will be needed to ensure
complete parasitological clearance while minimizing
selection for resistant genotypes. Thus, as an initial inves-
tigation, it would be appropriate to give women two or
three courses of IPTp during the antenatal period in a reg-
imen of 1,000 mg of azithromycin plus 600 mg chloro-
quine base, once daily for three days. Because rates of drug
absorption, distribution and excretion are commonly
altered during pregnancy, pharmacokinetic investigations
should be conducted as part of, or in parallel to, a clinical
trial.
Acceptance and adherence
Acceptance of and adherence to a three-day regimen of
azithromycin-chloroquine would be needed. In most
operational settings, the first dose of azithromycin-chlo-
roquine can be administered as directly observed therapy
during antenatal visits, but doses on the following two
days would require self-administration. Improvements in
adherence to multi-day regimens have been shown for
discrete treatment periods using pre-packaged sachets
labeled with pictogram instructions that are explained
during initial consultations [73-76]. Even so, achieving
high rates of adherence to a three-day azithromycin-chlo-
roquine regimen – administered two or three times during
pregnancy – would likely be a challenge. Public education
campaigns in recent years have discouraged chloroquine
use. Thus, community acceptance, even in a new combi-
nation, would require innovative packaging and market-
ing. Adherence could be improved if a three-dose
azithromycin-chloroquine fixed-dose formulation is
designed specifically for IPTp. In countries currently
implementing Home-based Management of Malaria and/
or the community component of the Integrated Manage-
ment of Childhood Illness, adherence to IPTp could be
improved further with community health workers making
house visits on days following antenatal consultations to
verify self-treatment while taking the opportunity to
develop or review an individualized perinatal plan in the
home.
Azithromycin plus SP is another option for IPTp which
would not present the disadvantage chloroquine-associ-
ated pruritus. However, SP may have surpassed a resist-
ance threshold which would make it an ineffective partner
drug. Alternatively, azithromycin could be combined with
piperaquine to improve adherence; piperaquine is at least
as effective as, and better tolerated than, chloroquine
against P. falciparum and P. vivax [77]. Pyronaridine is
another potential partner drug, shown to have additive
properties with azithromycin [78]. Mefloquine, despite
some important issues of tolerability, has the advantage
that it can be administered as a single, observed dose.
Optimal timing
SP is contraindicated prior to quickening due to its tera-
togenic risk and, again, one month prior to delivery
because of possible drug-induced kernicterus. Thus, pro-
viding IPTp with SP requires estimating gestational age
and delivery date with some accuracy. In contrast, there
are no known contraindications for azithromycin-chloro-
quine at any gestational age. This is important because
current IPTp guidelines are currently based on operational
convenience rather than the natural course of MIP [79].
Earlier IPTp administration may be important as maternal
parasite densities peak between nine and 16 weeks [1,3],
tapering until term. IPTp administration in the last month
of pregnancy may be of considerable value, too, increas-
ing foetal weight gain during final stages of accelerated
growth in utero [79].
Mefloquine may also be suitable for administration ear-
lier and later in pregnancy than SP. Based, in part, on post-
marketing surveys and retrospective studies which include
1271 first-trimester pregnancies, the US Centers for Dis-
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ease Control and the UK Health Protection Agency recom-
mend mefloquine chemoprophylaxis for pregnant
women in any trimester when travelling to areas of high
malaria transmission. Overall experience does not suggest
that mefloquine is teratogenic [16,80]. Administration in
the first trimester, however, may warrant caution in light
of two retrospective studies that found associations
between mefloquine exposure and spontaneous abortion
[81], and stillbirth [80].
ACTs are associated with embryotoxicity over a narrow
dose range in animal models of early pregnancy with
some additional evidence of lethality in second and third
trimesters [82]. For this reason, the WHO recommends
ACTs for curative purposes only during the second- and
third-trimesters if other treatments have been considered
unsuitable. First-trimester administration is contraindi-
cated unless treatment is considered life-saving for the
mother [83].
Potential additional benefits of azithromycin-chloroquine 
when used for IPTp
Use of the azithromycin-chloroquine combination in
IPTp may offer several additional public health benefits
over other possible replacements for SP.
Reduction of sexually transmitted infections
Sexually transmitted infections (STI) adversely affect preg-
nancy and contribute to pre-term delivery, LBW, intrauter-
ine growth-retardation, spontaneous abortion, stillbirth,
newborn morbidity and mortality [84]. Maternal health is
also jeopardized by STIs with potential complications
including pelvic inflammatory disease, ectopic pregnancy
and infertility [85]. Prevalence estimates of symptomatic
STIs at antenatal clinics in sub-Saharan Africa range
between 2.5 and 17% for syphilis [86-91], 1.7 and 7% for
Neisseria gonorrhoea [86-88,91-96], 5.3 to 20.8% for C. tra-
chomatis [86-88,92-95,97] and 7.3% to 62% for chancroid
[98].
In resource-limited settings, testing women for STIs dur-
ing antenatal consultations and providing appropriate
care has been a public health challenge for decades. To
assist countries, the WHO has developed syndromic-
based algorithms for the detection of STIs. In high-trans-
mission areas, the method is reliable for men, but much
less so for women. Syndromic diagnosis of N. gonorrhoea
and C. trachomatis among women has a sensitivity of 30 to
80% and a specificity of 40 to 80%; rarely does the sum of
the two exceed 120% [99-102]. An additional shortcom-
ing is that asymptomatic infection, a substantial portion
of disease burden, remains undetected and, thus,
untreated.
In South Africa's largest district, Hlabisa, 24.9% of females
between 15 and 49 years of age are estimated to have at
least one STI on any given day – Treponema pallidum, N.
gonorrhoea, C. trachomatis, or Trichomonas vaginalis. While
this prevalence may be higher than in some other parts of
sub-Saharan Africa, of particular concern is that 48% of
these infections are asymptomatic. In addition, just 2% of
women with symptomatic STIs ever seek treatment in Hla-
bisa, and when they do, only 65% of them receive ade-
quate care. Pregnant women are less likely to have
asymptomatic STIs compared to non-pregnant women
(17% vs. 59%), but the age-specific prevalence of infec-
tion is often twice as high for pregnant women [103]. This
level of disease prevalence, symptomatic and asympto-
matic, suggests a role for mass treatment during preg-
nancy.
The presumptive treatment of STIs in pregnancy improved
maternal health and birth outcomes in a randomized clin-
ical trial involving 4,033 pregnancies in Uganda [88]. Vag-
inal infections were significantly lower in women who
received a one-time dose of azithromycin (1,000 mg),
metronidazole (2,000 mg) and cefixime (400 mg) com-
pared to women who received iron/folate and low-dose
multivitamins. In the treatment group, the relative risk
(RR) of T. vaginalis was 0.28 (95% CI, 0.18–0.49), the RR
of bacterial vaginosis was 0.78 (95% CI, 0.69–0.87), and
the RR of infant ophthalmia was 0.37 (95% CI, 0.20–
0.70). The incidence of LBW was substantially reduced in
the intervention group (RR, 0.68; 95% CI, 0.53–0.86) as
was early neonatal mortality (25.4 per 1,000 live births),
when compared to the control group (29.1 per 1,000 live
births).
While difficult to attribute specific beneficial outcomes to
each compound, azithromycin probably had a considera-
ble effect. An oral dose of 1,000 mg of azithromycin clears
more than 90% of cervical infections due to N. gonorrhoea
and C. trachomatis [85]. The same dose will cure and pro-
vide chemoprophylaxis against chancroid and syphilis.
Studies in Uganda [104] and Tanzania [105] have shown
that azithromycin, 1,000 mg and 2,000 mg respectively, is
equally effective as benzathine penicillin G in treating
syphilis among non-pregnant adults. If untreated in preg-
nancy, one-third of women will develop congenital syph-
ilis, carrying major risk for the foetus. One study in
Tanzania found unscreened congenital syphilis associated
with 51% of stillbirths, 24% of pre-term live births and
17% of adverse pregnancy events [90]. Another trial in
Zambia implicated maternal syphilis in 42% of spontane-
ous abortions [106]. Despite the high cure rates observed
in the clinical trials of Uganda and Tanzania, 1,000 mg
and 2,000 mg of azithromycin given to five pregnant
women with syphilis in China did not prevent trans-pla-
cental infection [107]. Thus, IPTp with azithromycin-
chloroquine should not be viewed as a replacement for
benzathine penicillin G in the prevention of congenital
disease. However, azithromycin-chloroquine adminis-
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tered in IPTp may improve outcomes for the majority
women whose syphilis infections, both symptomatic and
asymptomatic, that are currently undiagnosed and
untreated.
The extent to which the control of STIs can prevent the
spread of HIV remains unknown. Observational studies
associate treatment of ulcerative STIs with reductions in
HIV transmission, particularly among men [108], and yet
a systematic review of eight clinical trials failed to find the
same relationship in seven of them [109]. It is possible
that two or three IPTp treatments with azithromycin-chlo-
roquine could offer women some protection against HIV
infection in pregnancy, but the observable difference may
be undetectable due to sample size limitations in most
clinical trials, especially in areas with low HIV prevalence
rates.
Chloroquine may offer its own protection against HIV
transmission. Cord blood containing high levels of chlo-
roquine has been associated with a reduced risk of
mother-to-child transmission (MTCT) of HIV [110]. In
addition, viral shedding in breast milk has been lowered
among HIV-positive women who received three days of
600 mg chloroquine as an anti-malarial chemoprophylac-
tic [111]. It is unknown whether this reduction in viral
load is sufficient to prevent HIV transmission among
mothers who choose to breastfeed.
Prevention of pneumococcal infection in pregnancy
Pneumonia is not a common focus of maternal health
packages in most resource-limited settings because the
incidence in pregnancy is not appreciably higher than in
non-pregnant women [112]. Disease progression, how-
ever, is substantially more virulent during gestation [113-
115]. There are old data from Ibadan, Nigeria, that suggest
the incidence of pneumococcal meningitis may increase
during pregnancy and puerperal period [116]. Facility
records between 1958 and 1962 revealed that 86% (26 of
31) of women with pneumococcal meningitis were preg-
nant (15) or had recently delivered (11). By comparison,
disproportionately fewer pregnant or early postpartum
women, 22% (7 of 32) in total, were diagnosed with other
types of meningitis. It is uncertain whether this enhanced
risk in pregnancy occurs in other parts of Africa. If so, then
it is conceivable that IPTp with azithromycin might pro-
vide some protection against this uncommon but very
serious infection.
Cost
The cost of 1,800 mg of chloroquine (600 mg per day for
three days) ranges between US $0.10 and $0.20, while
3,000 mg of azithromycin (1,000 mg per day for three
days) is approximately US $6.80 [117]. Thus, an azithro-
mycin-chloroquine IPTp regimen administered two or
three times would cost between US $14.00 and $21.00 per
pregnancy. This is prohibitively expensive for national
malaria control programmes in most endemic countries
in Africa. Thus, external funding would be required for
widespread implementation of the combination in IPTp.
This could take many forms: a direct donation from the
pharmaceutical industry, and/or a financing mechanism
modelled after the Global ACT Subsidy or the Interna-
tional Financing Facility for Immunization.
Azithromycin and selection for resistance
There are concerns that use of azithromycin-chloroquine
for IPT could encourage the emergence and spread of
resistance to a variety of organisms. Pathogens that need
to be considered include malaria parasites, organisms
causing STIs, and the pneumococcus.
Malaria parasites
Apart from clinical trials, azithromycin has never been
used operationally for treatment or prevention of malaria.
The susceptibility of azithromycin-chloroquine for select-
ing parasites resistant to azithromycin is, therefore,
unknown. The declining use of chloroquine throughout
sub-Saharan Africa is likely to lead to reversal of resistance
as witnessed in Malawi where parasite sensitivity returned
five years after suspending its use. It is possible the re-
introduction of chloroquine with azithromycin as a part-
ner drug may prevent re-selection of parasites carrying the
pfcrt resistance mutation. However, rigorous surveillance
would be needed to verify this assumption.
Organisms causing STIs
Azithromycin sensitivity patterns in high-income coun-
tries do not suggest that its use in IPTp would rapidly
induce resistance in N. gonorrhoea or C. trachomatis. Sensi-
tivity of the gonococcus remains relatively high, even in
the presence of growing penicillin resistance. In the
United States, minimum inhibitory concentrations
(MICs) of azithromycin exposed to gonococcal isolates
have increased modestly since 1992 when tracking began.
In 2006, 0.2% (14 of 6,089) of isolates provided through
a national network were resistant to azithromycin with a
MIC > 2.0 μg/ml, representing a slight decrease from 0.6%
(35 of 6,199) of isolates in 2005 [118]. In the case of C.
trachomatis, the most recent meta-analysis of 12 trials
involving 1,543 patients estimates cure rates to be 97%
with a single 1,000 mg dose of azithromycin [119].
There is greater concern regarding syphilis. Azithromycin
has been used, for example, since 1999 in San Francisco
(USA) for chemoprophylactic (1,000 mg) and curative
(2,000 mg) purposes against syphilis. By 2004, a muta-
tion associated with T. pallidum resistance to macrolides at
the A2058 position in the 23S rRNA gene was found in
56% blood samples from the main metropolitan sexual
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health centre. All isolates were from men who have sex
with men, 31% of which were from HIV-infected men
[120]. The rapid decline in sensitivity is likely attributable,
in large part, to underlying erythromycin resistance which
has been in general use for over 50 years. Erythromycin-
resistant T. pallidum isolates with mutation at the A2058
position confer resistance to macrolide antibiotics and are
associated with treatment failures [121,122]. Indeed, a
risk factor for being infected with azithromycin-resistant
syphilis is having used azithromycin or other macrolides
in the recent past [123,124].
The potential for rapid induction of T. pallidum resistance
in Africa is difficult to estimate since molecular analyses of
the A2058 region have not been included in most syphilis
studies of the region. In Madagascar, the mutation was not
found in analysis of 103 T. pallidum isolates and no azi-
thromycin treatment failures have been reported in coun-
try [123,125]. Because neither macrolide has been
deployed on any scale in focus countries of IPTp, azithro-
mycin may be less vulnerable to rapid loss of sensitivity as
has been witnessed in high-income countries.
The pneumococcus
Pneumococcal resistance to macrolides occurs by two pri-
mary mechanisms, each with distinct genetic markers:
ribosomal methylation (ermB or ermA genes) and efflux
pump mutation (mefA or mefE genes). Based on experi-
ence in mass treatment of trachoma with azithromycin,
there is concern that use of the azithromycin-chloroquine
combination for IPTp might increase the prevalence of
azithromycin- and erythromycin-resistant pneumococci.
Trachoma eradication campaigns using azithromycin
among vulnerable groups of children in Australia and
Nepal found that one-time treatment may select mac-
rolide-resistant pneumococcal strains in the nasopharynx
[126,127] and conjunctiva [128]. Selection, however, was
transient. In Australia, 98.7% (78 of 79) of nasopharyn-
geal pneumococcal isolates collected at baseline were sen-
sitive to azithromycin, decreasing to 84.2% (32 of 38)
between two to three weeks, and then 73% (27 of 37) at
two months. By six months, 94.9% of isolates were sensi-
tive to azithromycin [126]. One-year after a trachoma
campaign in Nepal, 86% (50 of 57) of randomly collected
isolates were positive for S. pneumoniae, and 100% (50 of
50) were azithromycin sensitive [129]. Selection of azi-
thromycin-resistant strains, however, has not always fol-
lowed trachoma treatment campaigns. Very high
macrolide sensitivity of nasopharyngeal pneumococci
was observed in Tanzania when samples were obtained at
three weeks, two months and six months post-treatment.
Of 4,782 pneumococcal swabs tested, only one demon-
strated pneumococcal resistance to azithromycin. Curi-
ously, the resistant sample was collected at six months,
not earlier, as might be expected with a treatment-induced
mutation [130].
Ways to reduce opportunity for resistance
A number of steps could be taken to reduce the chances
that azithromycin use in IPT might enhance macrolide
resistance in bacteria responsible for several major infec-
tions. Considerations include the following:
Setting dose and duration above resistance breakpoint
A counter-selective dose – the minimum dosage necessary
to prevent the emergence of drug resistance – can be used
instead of the conventional minimum required dose to
achieve adequate clinical and parasitological cure. Such a
dose, set just above the resistance breakpoint of target
micro-organisms, would suppress most pathogens during
initial drug exposure and sustain concentrations sufficient
to inhibit mutant progeny that might survive and select
for resistance. Breakpoints and a counter-selective dose for
azithromycin-chloroquine can be modelled using phar-
macokinetic and pharmacodynamic parameters in IPTp
target countries. While there will always be the potential
for inducing resistance, a multi-national, multi-centre sur-
veillance study over 10 years has shown that treatment of
respiratory tract infections to the point of bacterial eradi-
cation minimizes potential for selecting and maintaining
resistant strains [131].
Limiting availability
If azithromycin-chloroquine is limited to IPT, made avail-
able only through health facilities, and not simultane-
ously used for treatment purposes, then drug pressure can
be kept to a minimum.
Monitoring sensitivity of pneumococci
Coordinated resistance surveillance of pneumococci
should become a regional objective if countries choose to
adopt azithromycin-chloroquine for IPT. Regional net-
works already exist for monitoring malaria and pneumo-
coccal resistance, and could collaborate on this objective.
Monitoring, however, can be a source of controversy as
the relevance of in vitro macrolide sensitivity to clinical
outcomes is not well established. There has not been a
concomitant rise in S. pneumoniae case-mortality rates as
increasing macrolide resistance has been observed in vitro
[132]. A similar paradox has been seen with penicillin-
resistant S. pneumoniae [133,134]. Multiple reasons may
contribute to these discordant trends. In the case of newer
macrolides, including azithromycin, drug concentrations
are able to reach higher levels in the intracellular tissue
and in the epithelial lining fluid of the lung than concen-
trations measured in blood [135,136]. Azithromycin,
therefore, may have superior pharmacokinetics in vivo to
inhibit S. pneumoniae infection, safeguarding favourable
treatment outcomes in the face of increasing macrolide
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resistance as measured in vitro. However, macrolide efflux
pump mutations have been identified in S. pneumoniae
isolates with erythromycin MICs of at least 8 μg/mL – con-
centrations of azithromycin that have been associated
with clinical failures [137]. The in vitro-in vivo paradox
may be better understood with improved surveillance that
involves analysis of in vitro MICs and in vivo treatment
outcomes that include morbidity markers – not just mor-
bidity rates – which may be more sensitive in detecting the
effect of in vitro changes in macrolide resistance on clinical
outcomes [134].
Key scientific and programmatic questions
Evidence to date suggests that azithromycin-chloroquine
is a potential alternative for SP for IPTp and its evaluation
in clinical trials is warranted. Several scientific and pro-
grammatic questions need to be addressed, however, so
that policymakers and programme managers are able to
consider the merits of azithromycin-chloroquine in IPTp.
Key questions include:
1) Is azithromycin-chloroquine superior to SP and other
candidate replacements for IPTp in reducing LBW, mater-
nal anaemia and parasite clearance?
2) How much of the IPTp effect on birth weight, using azi-
thromycin-chloroquine, may be due to a reduction in
STIs, and what might be the savings, human and financial,
due to reduced STIs in pregnancy that could result?
3) Might administration of azithromycin-chloroquine
prior to quickening and within the last month of gestation
– periods contraindicated with SP – have additional effect
on LBW, maternal anaemia and parasite clearance?
4) Would the use of azithromycin-chloroquine for IPTp
result in more than transient changes in the sensitivity of
pneumococci to macrolides and penicillin?
5) How might countries monitor the effect of azithromy-
cin-chloroquine on the sensitivity of pneumococci to
macrolides?
6) What is the counter-selective dose for azithromycin-
chloroquine against malaria parasites, organisms causing
STIs, and pneumococci?
7) How would pregnant women respond to receiving azi-
thromycin-chloroquine and adhere to a regimen that
requires partial self-administration, particularly as infor-
mation campaigns have discouraged chloroquine use in
recent years?
8) Might IPTp with azithromycin-chloroquine reduce
maternal acquisition of HIV during pregnancy, in utero
MTCT or post-partum transmission among sero-positive
women who choose to breastfeed?
Conclusion
Azithromycin-chloroquine is a potential alternative to SP
for use in IPTp. The combination has demonstrated syner-
gism in vivo against P. falciparum in India. Preliminary
results of studies in non-pregnant adults in sub-Saharan
Africa have shown that azithromycin-chloroquine is not
inferior to mefloquine, a compound currently under con-
sideration for IPTp. The azithromycin-chloroquine com-
bination may be safely administered at any time in
pregnancy. The secondary benefits of the combination,
clearing of symptomatic and asymptomatic STIs, may be
as important to maternal, foetal and neonatal health as
the clearance and prevention of malaria. Innovative pric-
ing mechanisms would be required to introduce azithro-
mycin-chloroquine for IPTp since the drug cost per
pregnancy would otherwise be US $14.00 to $21.00 for
two or three courses. Close monitoring of antibiotic resist-
ance markers would need to be an essential part of any
IPTp programme using azithromycin-chloroquine.
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